Holen Sie sich die Stockscreener-App
15.58
1.02%
-0.16
Vorhandelsmarkt:
15.50
-0.08
-0.51%
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
(JANX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance
Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
What analysts say about Janux Therapeutics Inc stockFundamental Strength Indicators & High Return Investment Plans - earlytimes.in
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX) - MarketBeat
Analysts Unfazed By Janux’s Weaker Prostate Cancer Results - Citeline News & Insights
12/2/2025 Market UpdateWinners: XHLD, TLRY, HPPLosers: SONN, JANX, ABTCS&P 500: 0% - Trefis
Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Bank of America Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux tanks despite claiming positive trial results for JANX007 in mCRPC - The Pharma Letter
Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Alibaba Health Information Technology (OtherALBHF) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down - MSN
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy - geneonline.com
Janux shares halve despite still strong Phase I data - BioCentury
Janux stock falls as UBS maintains Buy rating despite disappointing data By Investing.com - Investing.com South Africa
Clear Street Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Janux Therapeutics stock price target lowered to $45 by H.C. Wainwright - Investing.com South Africa
Janux Therapeutics stock price target lowered to $150 by Cantor Fitzgerald - Investing.com Nigeria
Truist Securities reiterates Buy rating on Janux Therapeutics stock By Investing.com - Investing.com South Africa
Apple, Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Stock Movers: Boeing, Janux Therapeutics, Signet - Bloomberg.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Investors flee Janux after updated prostate cancer results disappoint - FirstWord Pharma
Janux Therapeutics stock hits 52-week low at 18.34 USD By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Janux T-cell engager data sink stock, but analysts still see best-in-class potential - Fierce Biotech
Janux dives as gaps in prostate cancer study data worry investors - MSN
Janux Therapeutics Stock Hits 52-Week Low After Trial Update - inkl
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair - BioPharma Dive
Janux stock falls as UBS maintains Buy rating despite disappointing data - Investing.com Nigeria
Janux Therapeutics (JANX) Stock: Why Did Shares Crash 41% on "Positive" News? - parameter.io
Applovin, MongoDB among market cap stock movers on Tuesday By Investing.com - Investing.com South Africa
Applovin, MongoDB among market cap stock movers on Tuesday - Investing.com
Truist Securities reiterates Buy rating on Janux Therapeutics stock - Investing.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Marvell, and More Movers - Barron's
Biggest stock movers Tuesday: CRDO, MDB, BA, and more - Seeking Alpha
Janux lets the genie out of the bottle | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings - Benzinga
Janux Therapeutics stock hits 52-week low at 18.34 USD - Investing.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):